Drugs / ChAdOx-1-S[recombinant]
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06189040 | May → Nov 2021 | COVID-19 | University of Antwerp | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04894435 Comparator | May 2021 → Nov 2024 overdue | COVID-19 | Canadian Immunization Research Network | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05710783 Comparator | Nov → Dec 2022 | COVID-19 | Laboratorio Avi-Mex, S.A. de C.V. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1-S [recombinant] | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04894435 ↗ |
| Known as | ChAdOx1 nCOV-19 | “The ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine is authorized to be given in two doses one month to 12 weeks apart.” NCT04894435 ↗1“Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine” NCT05710783 ↗ |
| Modality | Vaccine | “The ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine” NCT04894435 ↗ |
| Route | Intramuscular | “ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle” NCT04894435 ↗ |